Supply Chain
New research from Advisory Board, conducted in partnership with Staples Business, reveals how 102 health system supply chain and executive…
Sources claim Amazon is in early talks to potentially invest in Indian pharmacy chain MedPlus, Reuters reports, citing Indian news website FactorDaily.
The London-based generic drugmaker Hikma is allocating large supplies of hydromorphone to its U.S. hospital customers to help relieve the current injectable opioid shortage, the company announced July 18.
Mackenzie Bean
In a recent press release, Medtronic announced that is has received CE (Conformité Européenne) Mark for the MiniMed(TM) 670G hybrid closed loop system - the first and only system to automate and personalize the delivery of basal insulin 24 hours a…
In a recent press release, Medtronic announced that it has received U.S. Food and Drug Administration (FDA) approval for 200mm and 250mm lengths of the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon (DCB) to treat long superficial femoral artery (SFA) lesions in patients with…
Medpricer, the leading purchased services cost management solution for the healthcare industry, today shares three best practices healthcare organizations can implement to support healthcare sourcing. The healthcare supply chain is often misunderstood, underinvested and faces constant changes with the M&A…
Staff
President Donald Trump's tariffs on Chinese goods will increase healthcare costs, and this increase will be shouldered primarily by healthcare consumers, according to a report from the center-right nonprofit American Action Forum.
Amazon is in talks with Xealth, a startup that offers a digital prescribing and analytics platform, and two health systems about a pilot project that would enable physicians to recommend medical product bundles to their patients at the hospital and…
Here are the three latest drugs or medical devices approved by the FDA since July 5:
Amazon is seeking to improve its relationship with healthcare manufacturers and service providers, Bloomberg reports.
An ongoing investigation conducted by data analysts at Science found pattern of compensation by the drug industry to individuals in charge of FDA drug approvals.